These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 6961973)
21. Disposition of [3H]actinomycin D in tumor-bearing mice. Galbraith WM; Mellett LB Cancer Res; 1976 Apr; 36(4):1242-5. PubMed ID: 1063063 [TBL] [Abstract][Full Text] [Related]
22. [Antitumor action of cis-dichlorodiammineplatinum(II) and the effectiveness of a combination with sarcolysine]. Presnov MA; Konovalova AL; Romanova LF; Sof'ina ZP; Stetsenko AI Vopr Onkol; 1978; 24(4):53-60. PubMed ID: 654174 [TBL] [Abstract][Full Text] [Related]
23. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Rosen G; Tan C; Sanmaneechai A; Beattie EJ; Marcove R; Murphy ML Cancer; 1975 Mar; 35(3 suppl):936-45. PubMed ID: 1078642 [TBL] [Abstract][Full Text] [Related]
24. The effect of liposome (phospholipid vesicle) entrapment of actinomycin D and methotrexate on the in vivo treatment of sensitive and resistant solid murine tumours. Kaye SB; Boden JA; Ryman BE Eur J Cancer (1965); 1981 Mar; 17(3):279-89. PubMed ID: 6943028 [No Abstract] [Full Text] [Related]
25. Sustained release of adriamycin from implanted hydroxyapatite blocks for the treatment of experimental osteogenic sarcoma in mice. Itokazu M; Kumazawa S; Wada E; Wenyi Y Cancer Lett; 1996 Oct; 107(1):11-8. PubMed ID: 8913261 [TBL] [Abstract][Full Text] [Related]
26. Chemotherapeutic treatment of xenograft Spirocerca lupi-associated sarcoma in a murine model. Stettner N; Ranen E; Dank G; Lavy E; Brenner O; Harmelin A Comp Med; 2007 Jun; 57(3):267-71. PubMed ID: 17605341 [TBL] [Abstract][Full Text] [Related]
27. Approaches to combination chemotherapy in rat, mouse, and hamster tumors. Griswold DP; Dykes DJ; Kelley CA; Roberts BJ; Dominick CA Cancer Chemother Rep 2; 1974 Mar; 4(1):99-108. PubMed ID: 4524043 [No Abstract] [Full Text] [Related]
28. Melphalan sensitivity as a function of progressive metastatic growth in two subpopulations of a mouse mammary tumour. Miller BE; Miller FR; Machemer T; Heppner GH Br J Cancer; 1993 Jul; 68(1):18-25. PubMed ID: 8318410 [TBL] [Abstract][Full Text] [Related]
32. Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase. Horsman MR; Brown DM; Hirst DG; Brown JM Br J Cancer; 1986 Feb; 53(2):247-54. PubMed ID: 3006735 [TBL] [Abstract][Full Text] [Related]
33. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Houghton JA; Cook RL; Lutz PJ; Houghton PJ Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262 [TBL] [Abstract][Full Text] [Related]
34. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787 [TBL] [Abstract][Full Text] [Related]
35. A spontaneous transplantable osteogenic sarcoma in AKR/Ms mice. Nakakuki K; Shimokawa K; Yamauchi H; Ojima A Gan; 1976 Aug; 67(4):513-21. PubMed ID: 192624 [TBL] [Abstract][Full Text] [Related]
36. Host immune potentiation of drug responses to a murine mammary adenocarcinoma. II. Effect of melphalan therapy on the host immune system. Radov LA; Korn JH; Haskill JS Int J Cancer; 1976 Nov; 18(5):630-8. PubMed ID: 992900 [TBL] [Abstract][Full Text] [Related]
37. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434 [TBL] [Abstract][Full Text] [Related]
38. Studies on the cytotoxicity of penicillamine in a rat osteogenic sarcoma. Cosolo W; Christophidis N; Drummer OH; Findlay DM Clin Exp Pharmacol Physiol; 1986 Oct; 13(10):737-43. PubMed ID: 3467882 [TBL] [Abstract][Full Text] [Related]
39. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents. Brown JM; Hirst DG Br J Cancer; 1982 May; 45(5):700-8. PubMed ID: 7082556 [TBL] [Abstract][Full Text] [Related]
40. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells]. Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]